Background: Catatonia is a rare but life-threatening condition characterized by a constellation of psychomotor disturbances. The most widely used treatments of catatonia include benzodiazepines and electroconvulsive therapy. Despite the widespread use of benzodiazepines and the high response rate of catatonia to ECT, there are instances where catatonia does not respond to first-line treatments. This study aimed to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in managing catatonia.
Methods: A systematic literature search was conducted on the following databases: Medline, PubMed, Cochrane Library, Embase, PsycINFO and ClinicalTrials.gov for registered but not yet published studies.
Results: Out of 244 initially identified articles, there remained eight case reports and 1 case series eligible after screening. Of the twelve total cases, nine showed clinical improvement. However, there was significant heterogeneity in the complexity of the clinical situation, the severity of clinical features of catatonia, underlying causes, and rTMS treatment protocols between studies.
Conclusion: The results of this study are inconclusive. However, rTMS might be trialed for the management of catatonia when first-line treatment options fail, are unavailable, or need to be used with caution. Our review incorporating the most up to date evidence highlights the need for more extensive, standardized, randomized clinical trials to investigate the efficacy of rTMS for treating catatonia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajp.2024.104311 | DOI Listing |
Neurorehabil Neural Repair
January 2025
Institute for Health and Sport (IHeS), Victoria University, Melbourne, VIC, Australia.
Non-invasive brain stimulation (NIBS) is sometimes used alongside medication to alleviate motor symptoms in people with Parkinson's disease (PD). However, the evidence supporting NIBS's effectiveness for improving motor function in PD patients is uncertain. .
View Article and Find Full Text PDFSci Adv
January 2025
Experimental and Regenerative Neurosciences, The University of Western Australia, Perth, Australia.
Repetitive transcranial magnetic stimulation (rTMS) is commonly used to study the brain or as a treatment for neurological disorders, but the neural circuits and molecular mechanisms it affects remain unclear. To determine the molecular mechanisms of rTMS and the brain regions they occur in, we used spatial transcriptomics to map changes to gene expression across the mouse brain in response to two commonly used rTMS protocols. Our results revealed that rTMS alters the expression of genes related to several cellular processes and neural plasticity mechanisms across the brain, which was both brain region- and rTMS protocol-dependent.
View Article and Find Full Text PDFNeuromodulation
January 2025
Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Objectives: Biphasic sinusoidal repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation treatment that has been approved by the US Food and Drug Administration for treatment-resistant depression (TRD). Recent advances suggest that standard rTMS may be improved by altering the pulse shape; however, there is a paucity of research investigating pulse shape, owing primarily to the technologic limitations of currently available devices. This pilot study examined the feasibility, tolerability, and preliminary efficacy of biphasic and monophasic rectangular rTMS for TRD.
View Article and Find Full Text PDFPharmaceuticals (Basel)
November 2024
The Research Institute, The McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Glioblastoma multiforme is an aggressive malignancy with a dismal 5-year survival rate of 5-10%. Current therapeutic options are limited, due in part to drug exclusion by the blood-brain barrier (BBB). We have previously shown that high-amplitude repetitive transcranial magnetic stimulation (rTMS) in rats allowed the delivery across the BBB of an IGF signaling inhibitor-IGF-Trap.
View Article and Find Full Text PDFMedicina (Kaunas)
December 2024
Non-Invasive Neuromodulation Consortium for Mental Disorders, Society of Psychophysiology, Taipei 114, Taiwan.
Cognitive deficits are emerging as critical targets for managing schizophrenia and enhancing clinical and functional outcomes. These deficits are pervasive among individuals with schizophrenia, affecting various cognitive domains. Traditional pharmacotherapy and cognitive behavioral therapy (CBT) have limitations in effectively addressing cognitive impairments in this population.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!